Genome Editing of Hematopoietic Stem and Progenitor Cells
CRISPR-Cas9 genome editing of human hematopoietic stem and progenitor cells (HSPCs) has advanced our understanding of the mechanisms that regulate hematopoiesis and is contributing to the development of novel cellular therapies. However, genome editing of HSPCs can be challenging due to inefficient delivery and expression of the CRISPR-Cas9 components. Explore the protocols and resources below for support on how to perform high-efficiency genome editing of HSPCs in your own lab.
For detailed protocols developed specifically for our products, please consult the Product Information Sheet or enter the product keyword or catalog number below.
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not
share your email address with third parties. StemCell Technologies Inc. will use your email address to
confirm your identity and send you newsletters, transaction-related emails, promotional and customer
service emails in accordance with our privacy policy. You can change
your email preferences at any time.